The JPMorgan U.S. Tech Leaders ETF (JTEK) has been downgraded to a 'sell' rating due to its underperformance compared to peers and significant drawdowns. Despite a 17% drop in forward P/E since August, other tech ETFs show steeper valuation declines and better earnings growth prospects. JTEK's active strategy focuses on high growth over profitability, leading to deeper losses and slower recoveries historically. Investors may find better risk/reward profiles in alternatives like XLK and FTEC within the tech sector.

The JPMorgan U.S. Tech Leaders ETF (JTEK) is the subject, with Pluang's Technology sector market data as context. As of Nov 09, 2026 02:31 WIB, out of 150 priced US tech stocks on Pluang, 80 rose and 68 fell. Notable gainers include BTDR at USD 6.01 (+13.28%), QUBT at USD 6.33 (+12.43%), and AMD at USD 449.04 (+11.04%).

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Bitcoin Cash drops 4.5%, deepening weekly losses over 13% as Bitcoin holds steady near $75,800

Bitcoin Cash (BCH) fell about 4.5% on November 8, extending its weekly losses beyond 13%, while Bitcoin remained stable near $75,800. BCH's price dropped below key support levels around $250 and tested $244, signaling weaker demand compared to Bitcoi...